Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.6552W HIGH $684.00
Volume
792.50 K
Value Traded
257.81 K
Short % Float
16.44%
+116.9%Week
+117.4%1 Month
+11.55%3 Month
-81.07%6 Month
-96.41%5 Year
-96.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
21.91 M
EPS (TTM)
-11.97
P/E Ratio
-
Ent. Value
21.88 M
Total Shares
2.34 M
Float Shares
1.41 M
Insiders
39.84%
Institutions
6.50%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PMI Catalyst Timeline
Dated clinical, regulatory and corporate events for Picard Medical, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Picard Medical, Inc.
4Total events
3Upcoming
1Tier-1 (high impact)
2026 to 2029Coverage
Upcoming catalysts 2
Event history 1
Past FDA Catalysts and PDUFA Decisions
How PMI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Picard Medical, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PMI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SynCardia Total Artificial Heart | heart failure | 2026-03-02 | sustained clinical success in critically ill patients, improved outcomes in patients implanted earlier in their disease trajectory, strong recovery potential even in patients initially not eligible for transplant, and significant improvements in quality of life after early postoperative recovery. Renal and neurological outcomes remain major determinants of long-term success.Read More | Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PMI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PMI for Q2 2026. | ||||
PMI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PMI ranks across every disease it competes in
Competitive Position is a premium feature
See how PMI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPMI News
PMI▼ -7.9%on this news· ran to +190% by day 3
Picard Medical Reports Second Quarter 2026 Financial Results
Picard Medical reported a 39% increase in revenue for Q2 2026, totaling approximately $3.0 million. The company also achieved a gross profit of ~$0.6 million, a significant improvement from the prior year's loss. Despite a decrease in net loss, the company faces challenges with lower European sales and a continued high net loss. The development of the next-generation Emperor Total Artificial Heart platform is ongoing, with promising preclinical results.
Read more →PMI▲ +16.7%on this news
Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026
Picard Medical has unveiled the Emperor Total Artificial Heart architecture at the IEEE EMBC 2026, marking a significant milestone in its development. The presentation showcased the integration of the Emperor Drive System with SynCardia's proven Total Artificial Heart ventricles. This advancement aims to enhance the platform's implantability and patient outcomes, building on decades of clinical experience.
Read more →PMI▲ +16.7%on this newsshared move
Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026
Picard Medical will present its next-generation Emperor Total Artificial Heart technology at the IEEE EMBC 2026 conference. The presentation, led by Taha Hasekioglu, will introduce the Emperor Drive System architecture, showcasing advancements in total artificial heart technology. This marks a significant step in engineering innovation for mechanical circulatory support.
Read more →PMI▲ +16.7%on this newsshared move
Picard Medical Receives NYSE American Acceptance of Compliance Plan
Picard Medical, Inc. announced that the NYSE American has accepted its compliance plan, allowing the company to continue trading under the ticker PMI. The compliance period extends until November 8, 2027, during which the company aims to strengthen its financial position and advance its strategic initiatives. The acceptance reflects meaningful progress in their business and commitment to long-term growth.
Read more →PMI▼ -27.1%on this news· ran to -40% by day 3shared move
Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance
Picard Medical has announced a 1-for-50 reverse stock split to comply with NYSE American listing standards. The stock split, approved by shareholders, will take effect on July 31, 2026. This move aims to support the company's growth and enhance the adoption of its SynCardia Total Artificial Heart technology.
Read more →PMI▲ +6.5%on this news· ran to -20% by day 3
Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program
Picard Medical has published an independent commentary in Artificial Organs discussing its next-generation Emperor platform, which integrates with the SynCardia Total Artificial Heart. The commentary highlights successful preclinical studies demonstrating stable circulatory support and advanced design features. The Emperor platform aims to improve treatment options for patients with advanced heart failure.
Read more →PMI▼ -7.5%on this newsshared move
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
Picard Medical, Inc. has released a pre-recorded presentation ahead of its 2026 Annual Meeting, highlighting significant business performance and product development. The company reported an 85% increase in revenue for Q1 2026, driven by a surge in U.S. sales. The presentation also outlines ongoing initiatives for the next-generation Emperor platform, aiming for a fully implantable total artificial heart.
Read more →PMIPicard Medical Announces Leadership Transition
Picard Medical, Inc. announced a leadership transition with Patrick NJ Schnegelsberg stepping down as CEO, effective June 18, 2026. Richard Fang, Ph.D., has been appointed as Interim CEO while the search for a permanent replacement begins. Fang, who is also the Executive Chairman, has a strong background in medical devices and aims to continue advancing the company's mission.
Read more →PMIPicard Medical and SynCardia to Present New In Vivo Emperor Total Artificial Heart Data and Patient Outcome Research at ASAIO 2026
Picard Medical and SynCardia will present new data on the Emperor Total Artificial Heart and patient outcomes at the ASAIO 2026 Annual Conference. The presentations will showcase advancements in artificial heart technology and real-world impacts on patients. This participation highlights their leadership in mechanical circulatory support and ongoing commitment to innovation.
Read more →PMI▲ +60.3%on this news
Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies
Picard Medical has successfully completed preclinical studies for its next-generation Emperor Total Artificial Heart (TAH) at the University of Arizona. The studies demonstrated stable circulatory support and validated the independent dual motor design, which aims to enhance patient mobility. This progress marks a significant step towards developing a fully implantable artificial heart system.
Read more →PMIPICARD MEDICAL, INC. Issues Letter to Shareholders
Picard Medical, Inc. reported a strong start to 2026, with a significant revenue increase and positive gross profit margins. The company continues to focus on advancing its SynCardia Total Artificial Heart and developing the next-generation Emperor TAH. Despite challenges in profitability and regulatory uncertainties, the company is committed to improving its financial performance and expanding patient access to its life-saving technologies.
Read more →PMI▼ -8.4%on this news
Picard Medical / SynCardia Reports First Quarter 2026 Financial Results
Picard Medical, Inc. reported its first quarter 2026 financial results, showing an 85% revenue increase to $1.2 million and a return to positive gross profit. The company successfully reduced debt obligations and strengthened its capital structure. However, it also faced a net loss of $7.6 million and received notices of non-compliance from NYSE American regarding stockholders' equity. The company is preparing a compliance plan to address these issues.
Read more →PMI▼ -40.4%on this news
Medical Announces Pricing of $5 Million Offering
Picard Medical, Inc. has announced the pricing of a $5 million offering, which includes the sale of 16,666,667 shares of common stock and related warrants. The proceeds from the offering are intended for working capital and corporate purposes. This offering is set to close around May 6, 2026, pending customary conditions. The company, known for its SynCardia Total Artificial Heart, is using this opportunity to further bolster its financial position as it continues to lead in the artificial heart market.
Read more →PMI▼ -40.4%on this news
Picard Medical Announces Pricing of $5 Million Offering
Picard Medical, Inc. has announced the pricing of a $5 million offering, which includes shares of common stock and warrants. The offering is expected to close on May 6, 2026, and will provide funds for working capital and other corporate needs. The company is known for its SynCardia Total Artificial Heart, the only FDA-approved artificial heart in the U.S. and Canada.
Read more →PMIPicard Medical / SynCardia Recognizes Banner Health as Global Leader and Supporter in the Advancement of Total Artificial Heart Technology
Picard Medical has acknowledged Banner Health for its exceptional support in total artificial heart therapy, particularly in bridge-to-transplant cases. With over 50 successful implants of the SynCardia Total Artificial Heart, Banner Health demonstrates significant clinical expertise. The program is part of a broader initiative to enhance cardiac care for patients with advanced heart failure.
Read more →PMI▲ +6.7%on this news· ran to -19% by day 3
Picard Medical / SynCardia Reports Revenue Growth Based on Top-line Results for the First Quarter 2026
Picard Medical, the parent company of SynCardia Systems, reported a significant revenue increase of 79.9% for Q1 2026, reaching $1.1 million, compared to $0.6 million in Q1 2025. This growth was primarily attributed to increased demand for their SynCardia Total Artificial Heart and adjustments in driver rental pricing. CEO Patrick NJ Schnegelsberg emphasized the company's focus on expanding patient access and advancing their next-generation artificial heart technology. The company plans to file comprehensive financial results by May 15, 2026.
Read more →PMIPicard Medical / SynCardia to Present Next Generation Total Artificial Heart Platform at ISHLT 2026 in Toronto
Picard Medical will present its next-generation total artificial heart platform at the ISHLT 2026 Annual Meeting in Toronto. The event serves as a key forum for advancements in heart and lung failure treatments. Vice President Andre R. Simon will present a poster on the Emperor Total Artificial Heart, emphasizing ongoing innovations in mechanical circulatory support.
Read more →PMI▼ -8.8%on this news
Opening and Strategic Overview Patrick NJ Schnegelsberg, CEO
The article presents insights from a strategic overview led by CEO Patrick NJ Schnegelsberg, focusing on the collaboration between SynCardia and UCSF on Total Artificial Heart (TAH) implementations. Key topics discussed include the operational strategies and financial overview of the program, as well as patient selection criteria and institutional outcomes. Notably, UCSF is enhancing its status as a major center for heart transplantation, despite challenges reflected in the outcomes of some TAH patients. Future plans include collaborative outreach to improve best practices and expand the program's impact.
Read more →PMIPicard Medical Reports Full Year 2025 Financial Results
Picard Medical reported a 12.5% revenue growth for the year ended December 31, 2025, totaling $4.9 million. The company highlighted its successful public listing and improved financial position despite an increased net loss of $(27.0) million. The SynCardia Total Artificial Heart continues to gain traction in the market, with over 2,100 implants performed globally.
Read more →About Picard Medical, Inc.
Headquarters1992 E. SILVERLAKE RD., TUCSON, AZ, 85713
BIOPHARMAWATCH ELITE PLUS
Trade the next PMI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime